Table 2.
Most reported non-pregnancy-specific adverse event in VAERS
| Non-pregnancy-specific Adverse Events | Events Reported | %a |
|---|---|---|
| Headache | 482 | 2.21 |
| Fatigue | 472 | 2.16 |
| Pyrexia | 436 | 2.00 |
| Chills | 396 | 1.82 |
| Pain in extremity | 383 | 1.76 |
| Pain | 344 | 1.58 |
| Nausea | 320 | 1.47 |
| Dizziness | 228 | 1.05 |
| Myalgia | 198 | 0.91 |
| COVID-19 | 188 | 0.86 |
| Vomiting | 173 | 0.79 |
| SARS-CoV-2 test positive | 172 | 0.79 |
| Injection site pain | 150 | 0.69 |
| Vaccination site pain | 110 | 0.50 |
| Dyspnoea | 110 | 0.50 |
| Arthralgia | 109 | 0.50 |
| Malaise | 105 | 0.48 |
| Muscle spasms | 101 | 0.46 |
| Rash | 89 | 0.41 |
| Haemorrhage | 87 | 0.40 |
| Abdominal pain | 74 | 0.40 |
| Injection site erythema | 70 | 0.34 |
| Diarrhoea | 69 | 0.32 |
| Hyperhidrosis | 68 | 0.32 |
| Pruritus | 68 | 0.31 |
| Chest pain | 65 | 0.31 |
| Cough | 65 | 0.30 |
| Palpitations | 60 | 0.30 |
| Back pain | 57 | 0.28 |
| Heart rate increased | 56 | 0.26 |
| Paraesthesia | 55 | 0.26 |
| Oropharyngeal pain | 54 | 0.25 |
| Hypoaesthesia | 54 | 0.25 |
| SARS-CoV-2 test negative | 54 | 0.25 |
| Ultrasound scan abnormal | 54 | 0.25 |
| Injection site pruritus | 52 | 0.25 |
| Urticaria | 52 | 0.24 |
aThe percentages refer to the total number of AEs reported in the VAERS database